The purpose of this study is to identify promising treatments and compare them to determine which are most effective and then move into studies that can prove their effectiveness. The study will be conducted at up to 40 sites throughout the US with 200 patients being enrolled. Participants will receive one of several investigational products and then be evaluated for outcomes related to their overall improvement. They will be monitored at all times for safety and any adverse reactions to the products. Read More
Admitted to a hospital with symptoms suggestive of COVID-19 and requires ongoing medical care.
Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.
Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.
Male or non-pregnant female adult ≥18 years of age at t...
Study to evaluate reducing worry, anxiety, and stress in underserved communities highly impacted by the COVID-19 pandemic. Mindfulness Based Stress Reduction programs (meditation, breathing and movement) will be delivered via video / teleconference or a smart phone APP. The study lasts approximately 21 weeks. Read More
(1) age 18 years and older
(2) a baseline score ≥26 (clinically significant worry) on the Penn State Worry Questionnaire-Abbreviated
(3) fluency in English
(4) reside in one of the underserved, census-identified primarily African American communities in Buffalo, NY
(5) severe depression
(6) active suicidal intent
(7) DSM-V diagno...
Emergency department patients or adult companions of pediatric emergency department patients will take an anonymous survey. This survey will be used to determine the rate of Covid19 vaccinations in emergency rooms. Read More
Emergency Department patients or their adult companions
This study enrolls adults who have tested positive for COVID-19 and are currently hospitalized at Buffalo General Hospital or Millard Fillmore Hospital. The purpose is to learn whether immune study drugs that target inflammation can help with symptoms and recovery from COVID-19. 75% of the participants will receive study drug and 25% will receive placebo (no active ingredients). Neither the doctors or you will know which study drug or placebo you will receive. The study drug will either be : one time infliximab (Remicade) infusion in vein, one time abatacept (Orencia) infusion in vein, or 28 days of cenicriviroc (CVC) tablets. Most participants will also receive the anti-viral Remdesivir infusion in vein for maximum of 10 days. The study will last for about 60 days. Read More
Admitted to Buffalo General or Millard Fillmore Suburban or awaiting admission in the ED with symptoms suggestive of COVID-19.
Male or non-pregnant female adults ≥18 years of age at time of enrollment.
Has laboratory-confirmed (within 14 days prior to enrollment) SARS-CoV-2 infection as determined by PCR or other commercial or public health assay in any specimen.
This study enrolls adults with COVID-19 symptoms. The purpose of this study is to learn if an exploratory drug will lessen hospitalization and symptoms in people with COVID-19. Read More
Adults ages 18+.
Currently have COVID-19 symptoms that started in the past 3-5 days.
Have had a positive COVID-19 test or are willing to have a rapid antigen test (free if eligible).
Do not have chronic liver or kidney disease.
This study enrolls people who have tested positive for COVID-19 but are not hospitalized. The purpose of this study is to learn about how well the study medications improve the symptoms of COVID-19 and keep people from getting so sick that they have to be hospitalized. We will also want to learn how well people tolerate the study medicines. Read More
Adults ages 18+.
Have tested positive for COVID-19.
Not currently hospitalized.
This study enrolls healthy adults who will be getting a vaccine. The goal of this study is to learn about immune system cells called macrophages. Macrophages are important immune system cells that form when an infection is in the body. Read More
Adults ages 20-55.
Scheduled to receive a vaccine, like the COVID-19 or flu vaccine (for COVID-19 vaccine, study must be done before and after the first dose of the vaccine).
This study enrolls adults from the emergency department and the community who have a confirmed COVID-19 infection and can provide the results of their positive PCR testing for COVID. The purpose of this research study is to help us control the spread of COVID-19 by having accessible means of testing for the disease. If successful, this would allow individuals to determine if they have COVID-19 without leaving their home, which may limit the spread of the disease. We expect that you will be in this study for 1 day. A home collection kit will be brought to your home by a courier. You will be asked to use the home kit to prick your finger and place several drops of blood in a collection tube that we will have analyzed using the new test that we are studying. Once you have collected your blood you will place it in a mailing envelope with a prepaid label that we will provide and call delivery service. The delivery service will pick up your sample from your home and deliver it to us. You will also need to answer a few questions about your symptoms and your demographics with us by phone and provide a copy of your PCR COVID-19 test results. This study takes place in Buffalo, NY Read More
- Adults ages 18+
- Symptoms present for 25 days or less
- Patients who are confirmed positive for COVID-19 via PCR test.
- This study is not open for open enrollment: You may be invited to participate if you meet other eligibility criteria.
This study enrolls adults who have had a positive test for COVID-19. The purpose of this study is to learn more about how the infection works, including how the virus evolves and how a person infected with COVID-19's body responds. Knowing more about the virus at a cellular level will help scientists develop better treatments for this devastating disease. Read More
-Positive for COVID-19
-We will restrict asymptomatic enrollees to a maximum of 20% (100) participants. Once that number is achieved, symptoms of COVID-19 will be required for inclusion in to the study.
This study enrolls people with COVID-19 symptoms and a positive test result for COVID-19 (a free COVID-19 rapid antigen test is available for eligible participants). These symptoms include fever, chills, cough, nasal symptoms, body aches/muscle aches, headache, loss of smell, loss of taste, nausea, vomiting, diarrhea, fatigue, dizziness. The purpose of the study is to learn if a supplement will reduce inflammation and improve immune response in people with COVID-19. Read More
Adults ages 18+.
Females may not be pregnant at the time of enrollment.
Must have symptoms of COVID-19 and a positive test result.